The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The optimal sequencing of novel therapies in mantle cell lymphoma
In this video, Jonathon Cohen, MD, MS, Emory University School of Medicine, Atlanta, GA, shares some insights into the optimal sequencing of therapies in mantle cell lymphoma (MCL), commenting on how treatment options for patients have improved over the years with the introduction of novel immunotherapies. Dr Cohen then goes on to discuss treatment strategies for patients who relapse, which includes the use of Bruton’s tyrosine kinase (BTK) inhibitors and CAR-T cells. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
